slc25a43 Antibody

What is the SLC25A43 protein and its function in cellular biology?

SLC25A43 (Solute Carrier Family 25 Member 43) is a protein that belongs to the mitochondrial carrier family. This gene encodes a membrane protein located in the inner mitochondrial membrane and is involved in mitochondrial metabolism . The protein functions primarily in the transport of molecules across the mitochondrial membrane, though its specific substrate remains under investigation. Current research indicates its potential role in cell cycle regulation and cell proliferation, particularly in cancer cells . The molecular weight of SLC25A43 is approximately 38 kDa, and the protein is encoded by a gene located on the X chromosome (Gene ID: 194744) .

What antibody options are available for SLC25A43 detection in research applications?

Commercially available antibodies for SLC25A43 include polyclonal antibodies derived from rabbit hosts, such as the one described in the catalog ABIN6147932, which targets amino acids 1-100 of the human SLC25A43 protein . Additionally, antibodies like HPA035188 from Sigma-Aldrich have been validated for immunohistochemistry applications in research contexts . When selecting an antibody, researchers should consider the specific application (Western blotting, immunohistochemistry, etc.), species reactivity (most available antibodies show cross-reactivity with human, mouse, and rat), and the clonality (polyclonal versus monoclonal) based on their experimental design requirements.

How should SLC25A43 antibodies be stored and handled to maintain optimal reactivity?

SLC25A43 antibodies typically require storage at -20°C and should be kept in appropriate buffer conditions to maintain their functionality . For instance, the antibody described in the search results is preserved in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3. Researchers should avoid repeated freeze-thaw cycles as these can degrade antibody quality and reduce binding efficiency . When working with antibodies containing sodium azide, proper safety precautions should be followed as it is classified as a hazardous substance. For long-term storage, aliquoting the antibody into smaller volumes before freezing is recommended to minimize freeze-thaw cycles and preserve antibody integrity.

What methodological approaches are recommended for studying SLC25A43 expression in cancer tissues?

Research into SLC25A43 expression in cancer tissues has successfully employed a dual approach of gene and protein expression analysis:

For gene expression analysis:

• Tissue homogenization using mechanical methods (e.g., TissueLyserII with steel beads)

• RNA extraction using appropriate kits (e.g., AllPrep DNA/RNA/Protein Mini kit)

• cDNA conversion using reverse transcription kits

• Quantitative PCR using TaqMan Gene Expression assays for SLC25A43 (e.g., Hs00933775_m1)

• Normalization against reference genes such as ABL1 and β-actin

• Analysis using the 2^(-ΔΔCq) method for fold-change calculation

For protein expression analysis:

• Formalin fixation and paraffin embedding of tissue samples

• Antigen retrieval using appropriate buffers

• Incubation with anti-SLC25A43 antibody (e.g., HPA035188, dilution 1:175)

• Visualization using HRP-polymer detection systems

• Quantification using H-score method, evaluating intensity (0-3+) across multiple visual fields

This combined approach provides comprehensive insights into both transcriptional and translational regulation of SLC25A43 in cancer tissues.

How can researchers address the technical challenges in detecting low-abundance SLC25A43 protein expression?

Detection of low-abundance proteins like SLC25A43, particularly in tissues where baseline expression is already low, presents significant technical challenges. Researchers should consider:

• Optimized antigen retrieval: Testing multiple antigen retrieval methods (heat-induced epitope retrieval at varying pH conditions) to maximize epitope accessibility

• Signal amplification techniques: Employing tyramide signal amplification or similar methods to enhance detection sensitivity without increasing background

• Alternative detection methods: When immunohistochemistry yields limited results, consider more sensitive techniques such as:

  • Proximity ligation assay (PLA)

  • Immunoprecipitation followed by mass spectrometry

  • Fluorescence-based immunodetection with confocal microscopy

• Controls optimization: Utilize appropriate positive controls (tissues known to express higher levels of SLC25A43, such as liver or gallbladder) and negative controls

• Quantitative analysis: Implement digital image analysis software to detect subtle differences in staining intensity that might be missed by visual scoring alone

The inconsistency between gene expression data (which suggests high SLC25A43 expression in certain tissues) and protein detection (which often shows limited staining) highlights the importance of these technical considerations .

What is the current understanding of SLC25A43's role in cancer and how can researchers investigate functional implications?

Current research suggests that SLC25A43 may play a role in cell cycle regulation and cancer development:

• Gene expression studies have demonstrated significantly reduced SLC25A43 expression (50-83% decrease) in basal cell carcinomas compared to healthy skin, indicating a potential tumor-suppressive function

• Functional studies in HER2-positive breast cancer cells have shown that silencing SLC25A43 gene expression results in increased cell proliferation, further supporting its role in cell cycle regulation

• The protein may be involved in the altered metabolism observed in cancer cells (the Warburg effect), where cells favor glycolysis over oxidative phosphorylation

Researchers investigating functional implications should consider:

• Gene silencing experiments (siRNA, CRISPR-Cas9) to assess effects on cell proliferation, metabolism, and apoptosis

• Rescue experiments to confirm specificity of observed phenotypes

• Metabolomic analysis following SLC25A43 manipulation to identify affected metabolic pathways

• Cell cycle analysis using flow cytometry to determine specific phases affected by SLC25A43 alteration

• Xenograft models to assess in vivo relevance of SLC25A43 alterations

How does SLC25A43 expression differ between various tissue types and disease states?

Research indicates significant variation in SLC25A43 expression patterns across different tissues and between healthy and disease states:

These differences suggest tissue-specific regulation of SLC25A43 and potential diagnostic or prognostic value in cancer research . Interestingly, despite the differences in gene expression between healthy and cancerous tissues, no significant differences were observed between sexes, despite SLC25A43 being located on the X chromosome .

What controls should be included when validating SLC25A43 antibodies for research applications?

Proper validation of SLC25A43 antibodies requires a comprehensive set of controls:

• Positive tissue controls:

  • Liver and gallbladder tissues have been successfully used as positive controls for SLC25A43 staining according to antibody specifications

  • These tissues should show the expected subcellular localization pattern (mitochondrial distribution)

• Negative tissue controls:

  • Colon tissue has been used as a negative control for SLC25A43 staining

  • Ideally, researchers should also include tissues from SLC25A43 knockout models if available

• Technical controls:

  • Omission of primary antibody to assess non-specific binding of secondary detection systems

  • Isotype controls to evaluate non-specific binding of immunoglobulins

  • Absorption controls using the immunizing peptide to confirm specificity

• Cross-validation:

  • When possible, validate findings using multiple antibodies targeting different epitopes of SLC25A43

  • Confirm protein expression results with corresponding gene expression data

  • Validate findings using alternative detection methods (Western blot, mass spectrometry)

These controls are essential for ensuring the reliability and reproducibility of SLC25A43 detection in research applications.

What are the optimal protocols for quantifying SLC25A43 gene expression in experimental samples?

Based on published methodologies, the following protocol is recommended for accurate quantification of SLC25A43 gene expression:

• Sample preparation:

  • Homogenize frozen tissues using mechanical disruption (e.g., TissueLyserII with steel beads, 2 minutes at 20 Hz)

  • Extract total RNA using validated kits that maintain RNA integrity

  • Verify RNA quality and concentration using spectrophotometry (e.g., NanoDrop) and/or bioanalyzers

• cDNA synthesis:

  • Convert a standardized amount of RNA (e.g., 75 ng) to cDNA using high-capacity reverse transcription kits

  • Perform reactions in controlled temperature conditions following manufacturer recommendations

• qPCR setup:

  • Use validated TaqMan Gene Expression assays for SLC25A43 (e.g., Hs00933775_m1)

  • Include at least two reference genes (e.g., ABL1 and β-actin) for normalization

  • Run samples in duplicate or triplicate to assess technical variability

  • Include no-template controls and, if possible, no-RT controls

• PCR conditions:

  • Standard TaqMan cycling conditions: 50°C for 2 min, 95°C for 20 sec, followed by 40 cycles of 95°C for 1 sec and 60°C for 20 sec

• Data analysis:

  • Calculate normalized expression using the 2^(-ΔCq) method relative to reference genes

  • For comparing different conditions, use the 2^(-ΔΔCq) method to determine fold-changes

  • Apply appropriate statistical tests (e.g., paired t-test for comparing tumor vs. normal from the same individuals)

This methodology has successfully detected significant differences in SLC25A43 expression between basal cell carcinomas and healthy skin, with high reproducibility .

How can SLC25A43 antibodies be effectively utilized in Western blotting applications?

For successful Western blotting detection of SLC25A43 protein:

• Sample preparation:

  • Ensure efficient extraction of mitochondrial proteins using appropriate lysis buffers containing mild detergents

  • Include protease inhibitors to prevent degradation

  • Determine optimal protein loading amounts (typically 20-50 μg of total protein)

• Electrophoresis considerations:

  • Use appropriate percentage gels (10-12% SDS-PAGE) for the 38 kDa SLC25A43 protein

  • Include positive control samples (tissues known to express SLC25A43)

  • Use a reliable molecular weight marker

• Transfer and antibody incubation:

  • Optimize transfer conditions for mitochondrial membrane proteins (semi-dry or wet transfer)

  • Block with 5% non-fat milk or BSA in TBST

  • Incubate with SLC25A43 antibody at recommended dilutions (1:500 to 1:2000)

  • Use HRP-conjugated secondary antibodies appropriate for the host species (anti-rabbit for most SLC25A43 antibodies)

• Detection and analysis:

  • Employ enhanced chemiluminescence detection systems

  • For weak signals, consider longer exposure times or more sensitive detection methods

  • Verify specificity by expected molecular weight (38 kDa for SLC25A43)

  • Normalize to appropriate loading controls (e.g., mitochondrial markers like VDAC or cellular housekeeping proteins)

This approach allows for semi-quantitative assessment of SLC25A43 protein levels across different samples or experimental conditions.

What strategies should researchers employ when investigating the relationship between SLC25A43 expression and cancer progression?

To effectively investigate the relationship between SLC25A43 and cancer progression:

• Multi-level expression analysis:

  • Genomic: Assess copy number variations, mutations, or epigenetic modifications of SLC25A43

  • Transcriptomic: Measure gene expression using qPCR or RNA-seq

  • Proteomic: Quantify protein levels using Western blotting, immunohistochemistry, or mass spectrometry

  • Integrate data across these levels to identify discrepancies (e.g., post-transcriptional regulation)

• Clinical correlation studies:

  • Analyze SLC25A43 expression in tissue microarrays of cancer progression series

  • Correlate expression with clinicopathological parameters (tumor stage, grade, patient survival)

  • Compare expression between primary tumors and metastatic lesions

• Functional studies:

  • Manipulate SLC25A43 expression in cell lines using overexpression or knockdown approaches

  • Assess effects on:

    • Proliferation and cell cycle progression

    • Migration and invasion capabilities

    • Mitochondrial function and metabolic parameters

    • Resistance to apoptosis or therapy

• Mechanistic investigations:

  • Identify potential interacting partners through co-immunoprecipitation or proximity labeling

  • Determine signaling pathways affected by SLC25A43 alteration

  • Investigate the connection to the Warburg effect and other cancer-specific metabolic adaptations

• Animal models:

  • Develop conditional knockout models to assess the effect of SLC25A43 loss in specific tissues

  • Utilize xenograft models with modulated SLC25A43 expression to evaluate tumor growth in vivo

These comprehensive approaches will help establish whether SLC25A43 alterations are drivers or passengers in cancer progression and determine their potential as diagnostic markers or therapeutic targets.

What emerging techniques might enhance detection and functional analysis of SLC25A43 in research settings?

Several emerging technologies hold promise for advancing SLC25A43 research:

• Single-cell analysis:

  • Single-cell RNA sequencing to identify cell-specific expression patterns

  • Single-cell proteomics to detect SLC25A43 at the protein level in rare cell populations

  • Spatial transcriptomics to map SLC25A43 expression within tissue architecture

• Advanced imaging approaches:

  • Super-resolution microscopy for precise subcellular localization

  • Live-cell imaging with fluorescently tagged SLC25A43 to study dynamics

  • Multiplexed ion beam imaging (MIBI) or imaging mass cytometry for simultaneous detection of multiple markers alongside SLC25A43

• Functional genomics:

  • CRISPR-Cas9 screening to identify genetic interactions with SLC25A43

  • CRISPR activation/interference systems for precise modulation of SLC25A43 expression

  • Base editing approaches for introducing specific mutations to study structure-function relationships

• Metabolic analysis:

  • Metabolic flux analysis using stable isotope tracers to determine specific metabolic pathways affected by SLC25A43

  • Real-time assessment of mitochondrial function using Seahorse or similar technologies

  • Targeted metabolomics focusing on potential substrates of SLC25A43 transport

These advanced techniques could help overcome current limitations in SLC25A43 detection and provide deeper insights into its functional roles in normal physiology and disease states.

How might differences in SLC25A43 expression be leveraged for potential therapeutic applications?

The observed differences in SLC25A43 expression between normal and cancer tissues suggest several potential therapeutic approaches:

• Target identification:

  • Comprehensive characterization of metabolic vulnerabilities created by SLC25A43 downregulation

  • Identification of synthetic lethal interactions with SLC25A43 loss

  • Exploration of compensatory mechanisms activated in SLC25A43-deficient cells

• Therapeutic strategies:

  • Restoration of SLC25A43 expression through epigenetic modifiers if downregulation is due to methylation

  • Development of small molecules that mimic SLC25A43 function

  • Targeting of metabolic dependencies created by SLC25A43 loss

  • Combination approaches with standard therapies based on altered cellular energetics

• Biomarker development:

  • Validation of SLC25A43 expression as a prognostic or predictive biomarker

  • Development of companion diagnostics for therapies targeting SLC25A43-deficient tumors

  • Longitudinal monitoring of SLC25A43 expression during treatment

• Personalized medicine approaches:

  • Stratification of patients based on SLC25A43 expression profiles

  • Development of treatment algorithms incorporating SLC25A43 status

  • Integration with other molecular markers for comprehensive tumor profiling

Given the apparent role of SLC25A43 in cell proliferation and metabolism, therapies targeting these pathways in SLC25A43-deficient tumors might prove particularly effective and warrant further investigation .